University Hospital Southampton NHS Trust, Southampton, SO16 6YD, UK.
University of Southampton, Southampton, UK.
Urolithiasis. 2019 Apr;47(2):165-170. doi: 10.1007/s00240-018-1059-5. Epub 2018 Apr 25.
There is a lack of studies looking at the longitudinal follow-up of patients with cystine stones. We wanted to assess the journey of cystinuric patients through our specialist metabolic stone clinic to improve the understanding of episodes, interventions and current outcomes in this patient cohort. After ethical approval, all patients who attended our metabolic stone clinic from 1994 to 2014 with at least one cystine stone episode were included in our study. Data were retrospectively analysed for patient demographics, stone episodes or intervention, clinical parameters and patient compliance. Over a period of 21 years, 16 patients with a median age of 15.5 years underwent a mean follow-up of 8.6 years (1-21 years). The mean number of surgical interventions was 3.1 (1-8/patient), but patients who were stone free after their first treatment had lower recurrences (p = 0.91) and lower number of interventions during their follow-up (2.7/patient, compared to those who were not stone free at 4/patient). During their follow-up period, patients with < 3 interventions had a significantly better renal function than those with ≥ 3 surgical interventions (p = 0.04). Additionally, linear regression analysis showed that eGFR was demonstrated to decline with increasing numbers of stone episodes (r = 0.169). It was also noted that patients who began early medical management remained stone free during follow-up compared to those who had medical management after ≥ 2 stone episodes, of whom all had a recurrent episode. Our long-term longitudinal study of cystine stone formers highlights that patients who are stone free and receive early metabolic stone screening and medical management after their initial presentation have the lowest recurrence rates and tend to preserve their renal function. Hence, prompt referral for metabolic assessment, and the stone and fragments entirely removed (SaFER) principles are key to preventing stone episodes and improving long-term function.
目前缺乏对胱氨酸结石患者进行纵向随访的研究。我们希望通过我们的专业代谢性结石诊所评估胱氨酸尿患者的治疗过程,以提高对该患者人群发作、干预和当前结果的认识。在获得伦理批准后,我们将 1994 年至 2014 年间在我们代谢性结石诊所就诊且至少有一次胱氨酸结石发作的所有患者纳入研究。对患者的人口统计学数据、结石发作或干预、临床参数和患者依从性进行了回顾性分析。在 21 年的时间里,有 16 名中位年龄为 15.5 岁的患者接受了平均 8.6 年(1-21 年)的随访。平均手术干预次数为 3.1 次(1-8 次/患者),但首次治疗后结石消除的患者复发率较低(p=0.91),随访期间的干预次数也较少(2.7 次/患者,而未结石消除的患者为 4 次/患者)。在随访期间,接受<3 次干预的患者的肾功能明显好于接受≥3 次手术干预的患者(p=0.04)。此外,线性回归分析显示,eGFR 随着结石发作次数的增加而下降(r=0.169)。我们还注意到,与那些有≥2 次结石发作后才开始接受药物治疗的患者相比,早期开始药物治疗的患者在随访期间保持无结石状态,而后者所有患者均有结石再发。我们对胱氨酸结石形成者进行的长期纵向研究表明,无结石且在初次就诊后进行早期代谢性结石筛查和药物治疗的患者复发率最低,并且往往能够保留肾功能。因此,及时转介进行代谢评估以及完全去除结石和碎片(SaFER)原则是预防结石发作和改善长期功能的关键。